Phase 2 Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing and able to give your consent to take part in the trial
- You are 18 years old or older
- You have been diagnosed with advanced kidney cancer (renal cell carcinoma), confirmed by a laboratory test on a tissue sample
- You have been taking a stable dose of a cancer medication called cabozantinib (either 40 mg or 20 mg once daily) for at least 4 weeks, either on its own or combined with another medication called nivolumab
- You have been tolerating your current medication well, with a low likelihood of needing dose reductions or treatment breaks
- You are reasonably active and able to carry out daily activities, as measured by a standard medical scale (confirm with trial site)
- Your doctors estimate you have a life expectancy of at least 6 months
- No scans or checks to measure your cancer's response to treatment are planned during the study period
Who may not be able to join:
- You are unable to follow a recommended standard breakfast routine as part of the study (confirm with trial site)
- You have a stomach or bowel condition that affects how your body absorbs medication, such as inflammatory bowel disease, a malabsorption condition, or you have had major surgery on your stomach, pancreas, liver, or small intestine
- You have taken certain medications or foods that can affect how cabozantinib works in your body — including ketoconazole, grapefruit juice, clarithromycin, erythromycin, itraconazole, or ritonavir — within the past month (confirm with trial site)
- You have taken certain other medications that can reduce how well cabozantinib works — including rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John's Wort herbal preparations — within the past month
- You have taken certain other specific medications that can interact with cabozantinib — including cyclosporine, delavirdine, efavirenz, emtricitabine, benzbromarone, or probenecid — within the past month
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Tom van der Hulle, MD PhD, Leiden University Medical Center
Phone: 0031715263464
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Comparison of the AUC0-72h of the experimental and the standard regimen.; Comparison of blood trough concentration (Ctrough)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.